3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
561
Leukemia
282
Precursor Cell Lymphoblastic Leukemia-Lymphoma
235
Myelodysplastic Syndromes
110
Congenital Abnormalities
86
Leukemia, Monocytic, Acute
84
Leukemia, Myelomonocytic, Acute
82
Leukemia, Erythroblastic, Acute
75
Leukemia, Megakaryoblastic, Acute
72
Lymphoma
65
Burkitt Lymphoma
62
Recurrence
61
Leukemia, Myelomonocytic, Chronic
43
Leukemia, Biphenotypic, Acute
43
Lymphoma, Non-Hodgkin
41
Blast Crisis
37
Anemia, Refractory, with Excess of Blasts
36
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
35
Leukemia, Lymphocytic, Chronic, B-Cell
33
Lymphoma, Large B-Cell, Diffuse
30
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
28
Myeloproliferative Disorders
27
Lymphoma, Follicular
27
Lymphoma, Large-Cell, Immunoblastic
25
Lymphoma, Mantle-Cell
24
Leukemia, Myeloid, Chronic-Phase
23
Leukemia, Eosinophilic, Acute
23
Hodgkin Disease
23
Lymphoma, B-Cell, Marginal Zone
22
Leukemia, Basophilic, Acute
22
Interventions
eltrombopag
2
Cytarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Jacobs syndrome
×
Cytarabine
×
Other hematologic neoplasm
×
Clear all
NCT01656252
2020-11-03
PrE0901
PrECOG, LLC.
Phase 1/2
Terminated
15 enrolled
5 charts